| pubmed-article:2923957 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2923957 | lifeskim:mentions | umls-concept:C0008783 | lld:lifeskim |
| pubmed-article:2923957 | lifeskim:mentions | umls-concept:C0034414 | lld:lifeskim |
| pubmed-article:2923957 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2923957 | lifeskim:mentions | umls-concept:C0005508 | lld:lifeskim |
| pubmed-article:2923957 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2923957 | pubmed:dateCreated | 1989-5-2 | lld:pubmed |
| pubmed-article:2923957 | pubmed:abstractText | Elevations in quinidine steady-state serum concentrations have been reported in patients who received cimetidine concurrently. Studies in normal volunteers have shown that areas under the serum concentration-time curve of orally administered quinidine are higher when quinidine is given during chronic cimetidine therapy as compared to under control conditions. The mechanism for this interaction is generally ascribed to decreased hepatic clearance as a consequence of enzyme inhibition. In this study, we show that cimetidine also decreases the bioavailable fraction of quinidine. | lld:pubmed |
| pubmed-article:2923957 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2923957 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2923957 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2923957 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2923957 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2923957 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2923957 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2923957 | pubmed:issn | 0142-2782 | lld:pubmed |
| pubmed-article:2923957 | pubmed:author | pubmed-author:SchaalS FSF | lld:pubmed |
| pubmed-article:2923957 | pubmed:author | pubmed-author:BoudoulasHH | lld:pubmed |
| pubmed-article:2923957 | pubmed:author | pubmed-author:MacKichanJ... | lld:pubmed |
| pubmed-article:2923957 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2923957 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:2923957 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2923957 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2923957 | pubmed:pagination | 121-5 | lld:pubmed |
| pubmed-article:2923957 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2923957 | pubmed:meshHeading | pubmed-meshheading:2923957-... | lld:pubmed |
| pubmed-article:2923957 | pubmed:meshHeading | pubmed-meshheading:2923957-... | lld:pubmed |
| pubmed-article:2923957 | pubmed:meshHeading | pubmed-meshheading:2923957-... | lld:pubmed |
| pubmed-article:2923957 | pubmed:meshHeading | pubmed-meshheading:2923957-... | lld:pubmed |
| pubmed-article:2923957 | pubmed:meshHeading | pubmed-meshheading:2923957-... | lld:pubmed |
| pubmed-article:2923957 | pubmed:meshHeading | pubmed-meshheading:2923957-... | lld:pubmed |
| pubmed-article:2923957 | pubmed:meshHeading | pubmed-meshheading:2923957-... | lld:pubmed |
| pubmed-article:2923957 | pubmed:meshHeading | pubmed-meshheading:2923957-... | lld:pubmed |
| pubmed-article:2923957 | pubmed:articleTitle | Effect of cimetidine on quinidine bioavailability. | lld:pubmed |
| pubmed-article:2923957 | pubmed:affiliation | College of Pharmacy, Ohio State University, Columbus 43210. | lld:pubmed |
| pubmed-article:2923957 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2923957 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2923957 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2923957 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2923957 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:2923957 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
